Crossmark

340 Phase 1 study of AMG 160, a half-life extended BiTE® (bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer

Crossref DOI link: https://doi.org/10.1136/jitc-2020-SITC2020.0340

Published Online: 2020-12-10

Published Print: 2020-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Dorff, Tanya

Rettig, Matthew

Machiels, Jean-Pascal

Lolkema, Martijn

Autio, Karen

Greil, Richard

Rottey, Sylvie

Adra, Nabil

Salvati, Mark

Poon, Shirley

Tan, Daniel

Jurida, Gabor

Kouros-Mehr, Hosein

Fizazi, Karim

Tran, Ben

Horvath, Lisa
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct03792841 at ClinicalTrials.gov

Documents that mention this clinical trial

717 AMG 160, a prostate-specific membrane antigen (PSMA)-targeted BiTE<sup>®</sup> immuno-oncology therapy, is active in models of advanced prostate cancer that are resistant to radioligand therapy
https://doi.org/10.1136/jitc-2020-sitc2020.0717

340 Phase 1 study of AMG 160, a half-life extended BiTE® (bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer
https://doi.org/10.1136/jitc-2020-sitc2020.0340
License Information

License valid from 2020-12-09

Document is current

Any future updates will be listed below